Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor
Renal cell carcinomas (RCC) are a heterogeneous group of cancers that often include angiogenesis as a key clinical and pathological hallmark. As the transcription factor nuclear factor kappa B (NF-κB) has been identified as a key promoter of angiogenesis, NF-κB inhibitors could serve as potential an...
Gespeichert in:
| Veröffentlicht in: | Angiogenesis (London) 2009-12, Vol.12 (4), p.365-379 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 379 |
|---|---|
| container_issue | 4 |
| container_start_page | 365 |
| container_title | Angiogenesis (London) |
| container_volume | 12 |
| creator | Morais, Christudas Gobe, Glenda Johnson, David W. Healy, Helen |
| description | Renal cell carcinomas (RCC) are a heterogeneous group of cancers that often include angiogenesis as a key clinical and pathological hallmark. As the transcription factor nuclear factor kappa B (NF-κB) has been identified as a key promoter of angiogenesis, NF-κB inhibitors could serve as potential anti-angiogenic agents. In this study, we tested the anti-angiogenic properties of pyrrolidine dithiocarbamate (PDTC), a NF-κB inhibitor, using established in vitro and ex vivo assays in human umbilical vein endothelial cells (HUVEC) and human metastatic RCC cell lines (ACHN and SN12K1). In vitro, PDTC inhibited proliferation, capillary tube formation, invasion and trans-differentiation of HUVEC. Ex vivo, PDTC blocked vessel sprouting from aortic explants and disrupted the integrity of pre-formed vessels. PDTC also inhibited the adhesion of HUVEC and RCC cells to substratum and inhibited their invasion. PDTC inhibited RCC-induced proliferation of HUVEC. Protein microarray demonstrated heterogenic actions in each cell line: in HUVEC, epidermal growth factor was significantly decreased; in ACHN, basic fibroblast growth factor, growth related oncogene, interleukin-6, RANTES and monocyte chemoattractant protein-1 (MCP-1) were significantly decreased; and in SN12K1, MCP-1 was upregulated. PDTC increased the expression of the pro-angiogenic protein interleukin-8 in both RCC cell lines. Expression of vascular endothelial growth factor (VEGF) was not significantly altered, and exogenous VEGF had a neutral effect on in vitro angiogenesis of HUVEC. Collectively, these data suggest that PDTC has some anti-angiogenic properties, which may limit development and progression of RCC. |
| doi_str_mv | 10.1007/s10456-009-9158-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733611018</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1902628051</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-61b9d5df39f96a3ac44cb901c11566893738f81fdbbdccf7847c79db885e0e473</originalsourceid><addsrcrecordid>eNp1kE2LFDEQhoMo7rj6A7xIEMSL0aruztdxd_ELFrzoxUtIp5PZrD1Jm3Qf9t-bZQYXBE8FVc9bVTyEvER4jwDyQ0UYuGAAmmnkisEjskMueyY70I_JDrTQTGgJZ-RZrbfQQKGGp-QMtVIdYrcjPy_SGplN-5j3PkVHrVtjTpXmQJe7UvIcp5g8neJ6E7OzZbQHu_p31NK0udnbQkOL5EJ_2WWx9JLGdBPH2DrPyZNg5-pfnOo5-fHp4_erL-z62-evVxfXzA0AKxM46olPoddBC9tbNwxu1IAOkQuhdC97FRSGaRwn54JUg3RST6NS3IMfZH9O3h73LiX_3nxdzSFW5-fZJp-3amTfC0RA1cjX_5C3eSupPWeajUFyzUWD8Ai5kmstPpilxIMtdwbB3Gs3R-2m2TT32g20zKvT4m08-OkhcfLcgDcnwFZn51BscrH-5boOpRiAN647crWN0t6Xhw__f_0P5x-aBQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>211475956</pqid></control><display><type>article</type><title>Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Morais, Christudas ; Gobe, Glenda ; Johnson, David W. ; Healy, Helen</creator><creatorcontrib>Morais, Christudas ; Gobe, Glenda ; Johnson, David W. ; Healy, Helen</creatorcontrib><description>Renal cell carcinomas (RCC) are a heterogeneous group of cancers that often include angiogenesis as a key clinical and pathological hallmark. As the transcription factor nuclear factor kappa B (NF-κB) has been identified as a key promoter of angiogenesis, NF-κB inhibitors could serve as potential anti-angiogenic agents. In this study, we tested the anti-angiogenic properties of pyrrolidine dithiocarbamate (PDTC), a NF-κB inhibitor, using established in vitro and ex vivo assays in human umbilical vein endothelial cells (HUVEC) and human metastatic RCC cell lines (ACHN and SN12K1). In vitro, PDTC inhibited proliferation, capillary tube formation, invasion and trans-differentiation of HUVEC. Ex vivo, PDTC blocked vessel sprouting from aortic explants and disrupted the integrity of pre-formed vessels. PDTC also inhibited the adhesion of HUVEC and RCC cells to substratum and inhibited their invasion. PDTC inhibited RCC-induced proliferation of HUVEC. Protein microarray demonstrated heterogenic actions in each cell line: in HUVEC, epidermal growth factor was significantly decreased; in ACHN, basic fibroblast growth factor, growth related oncogene, interleukin-6, RANTES and monocyte chemoattractant protein-1 (MCP-1) were significantly decreased; and in SN12K1, MCP-1 was upregulated. PDTC increased the expression of the pro-angiogenic protein interleukin-8 in both RCC cell lines. Expression of vascular endothelial growth factor (VEGF) was not significantly altered, and exogenous VEGF had a neutral effect on in vitro angiogenesis of HUVEC. Collectively, these data suggest that PDTC has some anti-angiogenic properties, which may limit development and progression of RCC.</description><identifier>ISSN: 0969-6970</identifier><identifier>EISSN: 1573-7209</identifier><identifier>DOI: 10.1007/s10456-009-9158-0</identifier><identifier>PMID: 19882112</identifier><identifier>CODEN: AGIOFT</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Amino Acid Sequence ; Angiogenesis Inhibitors - pharmacology ; Animals ; Aorta - cytology ; Apoptosis - drug effects ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Blood and lymphatic vessels ; Cancer Research ; Carcinoma, Renal Cell - pathology ; Carcinoma, Renal Cell - secondary ; Cardiology ; Cardiology. Vascular system ; Cell Biology ; Cell Division - drug effects ; Cell Line, Tumor - drug effects ; Cell Transdifferentiation - drug effects ; Cells, Cultured - cytology ; Cells, Cultured - drug effects ; Coronary heart disease ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Endothelial Cells - cytology ; Endothelial Cells - drug effects ; Female ; Gene Expression Regulation, Neoplastic - drug effects ; Heart ; Humans ; Kidney Neoplasms - pathology ; Medical sciences ; Molecular Sequence Data ; Neoplasm Proteins - biosynthesis ; Neoplasm Proteins - genetics ; Neovascularization, Pathologic - drug therapy ; Neovascularization, Physiologic - drug effects ; NF-kappa B - antagonists & inhibitors ; Oncology ; Ophthalmology ; Organ Culture Techniques ; Original Paper ; Peptides - pharmacology ; Proline - analogs & derivatives ; Proline - pharmacology ; Rats ; Rats, Sprague-Dawley ; Thiocarbamates - pharmacology ; Umbilical Veins - cytology ; Vascular Endothelial Growth Factor A - biosynthesis</subject><ispartof>Angiogenesis (London), 2009-12, Vol.12 (4), p.365-379</ispartof><rights>Springer Science+Business Media B.V. 2009</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-61b9d5df39f96a3ac44cb901c11566893738f81fdbbdccf7847c79db885e0e473</citedby><cites>FETCH-LOGICAL-c400t-61b9d5df39f96a3ac44cb901c11566893738f81fdbbdccf7847c79db885e0e473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10456-009-9158-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10456-009-9158-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22176405$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19882112$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morais, Christudas</creatorcontrib><creatorcontrib>Gobe, Glenda</creatorcontrib><creatorcontrib>Johnson, David W.</creatorcontrib><creatorcontrib>Healy, Helen</creatorcontrib><title>Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor</title><title>Angiogenesis (London)</title><addtitle>Angiogenesis</addtitle><addtitle>Angiogenesis</addtitle><description>Renal cell carcinomas (RCC) are a heterogeneous group of cancers that often include angiogenesis as a key clinical and pathological hallmark. As the transcription factor nuclear factor kappa B (NF-κB) has been identified as a key promoter of angiogenesis, NF-κB inhibitors could serve as potential anti-angiogenic agents. In this study, we tested the anti-angiogenic properties of pyrrolidine dithiocarbamate (PDTC), a NF-κB inhibitor, using established in vitro and ex vivo assays in human umbilical vein endothelial cells (HUVEC) and human metastatic RCC cell lines (ACHN and SN12K1). In vitro, PDTC inhibited proliferation, capillary tube formation, invasion and trans-differentiation of HUVEC. Ex vivo, PDTC blocked vessel sprouting from aortic explants and disrupted the integrity of pre-formed vessels. PDTC also inhibited the adhesion of HUVEC and RCC cells to substratum and inhibited their invasion. PDTC inhibited RCC-induced proliferation of HUVEC. Protein microarray demonstrated heterogenic actions in each cell line: in HUVEC, epidermal growth factor was significantly decreased; in ACHN, basic fibroblast growth factor, growth related oncogene, interleukin-6, RANTES and monocyte chemoattractant protein-1 (MCP-1) were significantly decreased; and in SN12K1, MCP-1 was upregulated. PDTC increased the expression of the pro-angiogenic protein interleukin-8 in both RCC cell lines. Expression of vascular endothelial growth factor (VEGF) was not significantly altered, and exogenous VEGF had a neutral effect on in vitro angiogenesis of HUVEC. Collectively, these data suggest that PDTC has some anti-angiogenic properties, which may limit development and progression of RCC.</description><subject>Amino Acid Sequence</subject><subject>Angiogenesis Inhibitors - pharmacology</subject><subject>Animals</subject><subject>Aorta - cytology</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Blood and lymphatic vessels</subject><subject>Cancer Research</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Carcinoma, Renal Cell - secondary</subject><subject>Cardiology</subject><subject>Cardiology. Vascular system</subject><subject>Cell Biology</subject><subject>Cell Division - drug effects</subject><subject>Cell Line, Tumor - drug effects</subject><subject>Cell Transdifferentiation - drug effects</subject><subject>Cells, Cultured - cytology</subject><subject>Cells, Cultured - drug effects</subject><subject>Coronary heart disease</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Endothelial Cells - cytology</subject><subject>Endothelial Cells - drug effects</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic - drug effects</subject><subject>Heart</subject><subject>Humans</subject><subject>Kidney Neoplasms - pathology</subject><subject>Medical sciences</subject><subject>Molecular Sequence Data</subject><subject>Neoplasm Proteins - biosynthesis</subject><subject>Neoplasm Proteins - genetics</subject><subject>Neovascularization, Pathologic - drug therapy</subject><subject>Neovascularization, Physiologic - drug effects</subject><subject>NF-kappa B - antagonists & inhibitors</subject><subject>Oncology</subject><subject>Ophthalmology</subject><subject>Organ Culture Techniques</subject><subject>Original Paper</subject><subject>Peptides - pharmacology</subject><subject>Proline - analogs & derivatives</subject><subject>Proline - pharmacology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Thiocarbamates - pharmacology</subject><subject>Umbilical Veins - cytology</subject><subject>Vascular Endothelial Growth Factor A - biosynthesis</subject><issn>0969-6970</issn><issn>1573-7209</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kE2LFDEQhoMo7rj6A7xIEMSL0aruztdxd_ELFrzoxUtIp5PZrD1Jm3Qf9t-bZQYXBE8FVc9bVTyEvER4jwDyQ0UYuGAAmmnkisEjskMueyY70I_JDrTQTGgJZ-RZrbfQQKGGp-QMtVIdYrcjPy_SGplN-5j3PkVHrVtjTpXmQJe7UvIcp5g8neJ6E7OzZbQHu_p31NK0udnbQkOL5EJ_2WWx9JLGdBPH2DrPyZNg5-pfnOo5-fHp4_erL-z62-evVxfXzA0AKxM46olPoddBC9tbNwxu1IAOkQuhdC97FRSGaRwn54JUg3RST6NS3IMfZH9O3h73LiX_3nxdzSFW5-fZJp-3amTfC0RA1cjX_5C3eSupPWeajUFyzUWD8Ai5kmstPpilxIMtdwbB3Gs3R-2m2TT32g20zKvT4m08-OkhcfLcgDcnwFZn51BscrH-5boOpRiAN647crWN0t6Xhw__f_0P5x-aBQ</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>Morais, Christudas</creator><creator>Gobe, Glenda</creator><creator>Johnson, David W.</creator><creator>Healy, Helen</creator><general>Springer Netherlands</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20091201</creationdate><title>Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor</title><author>Morais, Christudas ; Gobe, Glenda ; Johnson, David W. ; Healy, Helen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-61b9d5df39f96a3ac44cb901c11566893738f81fdbbdccf7847c79db885e0e473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Amino Acid Sequence</topic><topic>Angiogenesis Inhibitors - pharmacology</topic><topic>Animals</topic><topic>Aorta - cytology</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Blood and lymphatic vessels</topic><topic>Cancer Research</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Carcinoma, Renal Cell - secondary</topic><topic>Cardiology</topic><topic>Cardiology. Vascular system</topic><topic>Cell Biology</topic><topic>Cell Division - drug effects</topic><topic>Cell Line, Tumor - drug effects</topic><topic>Cell Transdifferentiation - drug effects</topic><topic>Cells, Cultured - cytology</topic><topic>Cells, Cultured - drug effects</topic><topic>Coronary heart disease</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Endothelial Cells - cytology</topic><topic>Endothelial Cells - drug effects</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic - drug effects</topic><topic>Heart</topic><topic>Humans</topic><topic>Kidney Neoplasms - pathology</topic><topic>Medical sciences</topic><topic>Molecular Sequence Data</topic><topic>Neoplasm Proteins - biosynthesis</topic><topic>Neoplasm Proteins - genetics</topic><topic>Neovascularization, Pathologic - drug therapy</topic><topic>Neovascularization, Physiologic - drug effects</topic><topic>NF-kappa B - antagonists & inhibitors</topic><topic>Oncology</topic><topic>Ophthalmology</topic><topic>Organ Culture Techniques</topic><topic>Original Paper</topic><topic>Peptides - pharmacology</topic><topic>Proline - analogs & derivatives</topic><topic>Proline - pharmacology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Thiocarbamates - pharmacology</topic><topic>Umbilical Veins - cytology</topic><topic>Vascular Endothelial Growth Factor A - biosynthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morais, Christudas</creatorcontrib><creatorcontrib>Gobe, Glenda</creatorcontrib><creatorcontrib>Johnson, David W.</creatorcontrib><creatorcontrib>Healy, Helen</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Angiogenesis (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morais, Christudas</au><au>Gobe, Glenda</au><au>Johnson, David W.</au><au>Healy, Helen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor</atitle><jtitle>Angiogenesis (London)</jtitle><stitle>Angiogenesis</stitle><addtitle>Angiogenesis</addtitle><date>2009-12-01</date><risdate>2009</risdate><volume>12</volume><issue>4</issue><spage>365</spage><epage>379</epage><pages>365-379</pages><issn>0969-6970</issn><eissn>1573-7209</eissn><coden>AGIOFT</coden><abstract>Renal cell carcinomas (RCC) are a heterogeneous group of cancers that often include angiogenesis as a key clinical and pathological hallmark. As the transcription factor nuclear factor kappa B (NF-κB) has been identified as a key promoter of angiogenesis, NF-κB inhibitors could serve as potential anti-angiogenic agents. In this study, we tested the anti-angiogenic properties of pyrrolidine dithiocarbamate (PDTC), a NF-κB inhibitor, using established in vitro and ex vivo assays in human umbilical vein endothelial cells (HUVEC) and human metastatic RCC cell lines (ACHN and SN12K1). In vitro, PDTC inhibited proliferation, capillary tube formation, invasion and trans-differentiation of HUVEC. Ex vivo, PDTC blocked vessel sprouting from aortic explants and disrupted the integrity of pre-formed vessels. PDTC also inhibited the adhesion of HUVEC and RCC cells to substratum and inhibited their invasion. PDTC inhibited RCC-induced proliferation of HUVEC. Protein microarray demonstrated heterogenic actions in each cell line: in HUVEC, epidermal growth factor was significantly decreased; in ACHN, basic fibroblast growth factor, growth related oncogene, interleukin-6, RANTES and monocyte chemoattractant protein-1 (MCP-1) were significantly decreased; and in SN12K1, MCP-1 was upregulated. PDTC increased the expression of the pro-angiogenic protein interleukin-8 in both RCC cell lines. Expression of vascular endothelial growth factor (VEGF) was not significantly altered, and exogenous VEGF had a neutral effect on in vitro angiogenesis of HUVEC. Collectively, these data suggest that PDTC has some anti-angiogenic properties, which may limit development and progression of RCC.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>19882112</pmid><doi>10.1007/s10456-009-9158-0</doi><tpages>15</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0969-6970 |
| ispartof | Angiogenesis (London), 2009-12, Vol.12 (4), p.365-379 |
| issn | 0969-6970 1573-7209 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733611018 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Amino Acid Sequence Angiogenesis Inhibitors - pharmacology Animals Aorta - cytology Apoptosis - drug effects Biological and medical sciences Biomedical and Life Sciences Biomedicine Blood and lymphatic vessels Cancer Research Carcinoma, Renal Cell - pathology Carcinoma, Renal Cell - secondary Cardiology Cardiology. Vascular system Cell Biology Cell Division - drug effects Cell Line, Tumor - drug effects Cell Transdifferentiation - drug effects Cells, Cultured - cytology Cells, Cultured - drug effects Coronary heart disease Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Endothelial Cells - cytology Endothelial Cells - drug effects Female Gene Expression Regulation, Neoplastic - drug effects Heart Humans Kidney Neoplasms - pathology Medical sciences Molecular Sequence Data Neoplasm Proteins - biosynthesis Neoplasm Proteins - genetics Neovascularization, Pathologic - drug therapy Neovascularization, Physiologic - drug effects NF-kappa B - antagonists & inhibitors Oncology Ophthalmology Organ Culture Techniques Original Paper Peptides - pharmacology Proline - analogs & derivatives Proline - pharmacology Rats Rats, Sprague-Dawley Thiocarbamates - pharmacology Umbilical Veins - cytology Vascular Endothelial Growth Factor A - biosynthesis |
| title | Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T10%3A09%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-angiogenic%20actions%20of%20pyrrolidine%20dithiocarbamate,%20a%20nuclear%20factor%20kappa%20B%20inhibitor&rft.jtitle=Angiogenesis%20(London)&rft.au=Morais,%20Christudas&rft.date=2009-12-01&rft.volume=12&rft.issue=4&rft.spage=365&rft.epage=379&rft.pages=365-379&rft.issn=0969-6970&rft.eissn=1573-7209&rft.coden=AGIOFT&rft_id=info:doi/10.1007/s10456-009-9158-0&rft_dat=%3Cproquest_cross%3E1902628051%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=211475956&rft_id=info:pmid/19882112&rfr_iscdi=true |